Tolerx Inc.
CAMBRIDGE, Massachusetts, January 7 - Tolerx, Inc., today announced the completion of patient enrollment in its
Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy
of otelixizumab, a targeted T cell immunomodulator, in patients with
new-onset autoimmune type 1 diabetes.
